1. Home
  2. MLYS vs USNA Comparison

MLYS vs USNA Comparison

Compare MLYS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • USNA
  • Stock Information
  • Founded
  • MLYS 2019
  • USNA 1992
  • Country
  • MLYS United States
  • USNA United States
  • Employees
  • MLYS N/A
  • USNA N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • USNA Medicinal Chemicals and Botanical Products
  • Sector
  • MLYS Health Care
  • USNA Health Care
  • Exchange
  • MLYS Nasdaq
  • USNA Nasdaq
  • Market Cap
  • MLYS 1.0B
  • USNA 565.2M
  • IPO Year
  • MLYS 2023
  • USNA 1996
  • Fundamental
  • Price
  • MLYS $14.80
  • USNA $32.95
  • Analyst Decision
  • MLYS Strong Buy
  • USNA Hold
  • Analyst Count
  • MLYS 4
  • USNA 1
  • Target Price
  • MLYS $27.00
  • USNA $36.00
  • AVG Volume (30 Days)
  • MLYS 903.4K
  • USNA 149.7K
  • Earning Date
  • MLYS 08-12-2025
  • USNA 07-22-2025
  • Dividend Yield
  • MLYS N/A
  • USNA N/A
  • EPS Growth
  • MLYS N/A
  • USNA N/A
  • EPS
  • MLYS N/A
  • USNA 1.82
  • Revenue
  • MLYS N/A
  • USNA $876,242,000.00
  • Revenue This Year
  • MLYS N/A
  • USNA $13.04
  • Revenue Next Year
  • MLYS N/A
  • USNA $7.36
  • P/E Ratio
  • MLYS N/A
  • USNA $18.09
  • Revenue Growth
  • MLYS N/A
  • USNA N/A
  • 52 Week Low
  • MLYS $8.24
  • USNA $23.10
  • 52 Week High
  • MLYS $18.38
  • USNA $48.85
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 53.41
  • USNA 63.95
  • Support Level
  • MLYS $13.44
  • USNA $32.01
  • Resistance Level
  • MLYS $14.70
  • USNA $33.95
  • Average True Range (ATR)
  • MLYS 0.67
  • USNA 0.87
  • MACD
  • MLYS 0.12
  • USNA 0.15
  • Stochastic Oscillator
  • MLYS 99.44
  • USNA 76.58

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

Share on Social Networks: